R&D

30 July 2025 · WHO Essential Medicines List

The Selection and Use of Essential Medicines 2025

30 July 2025R&D
The Selection and Use of Essential Medicines 2025

The WHO Expert Committee recommended adding ravidasvir to the core Essential Medicines List (EML) as a therapeutic alternative under the square box listing for pangenotypic direct-acting antivirals used to treat chronic Hepatitis C in adults. When combined with sofosbuvir, ravidasvir provides a pangenotypic, broad-spectrum antiviral option, with evidence showing effectiveness and safety comparable to other approved pangenotypic regimens.

This item summarises coverage published by WHO Essential Medicines List.

Read the full article
Back to News & Events
R&DPharco Group

Press & media inquiries

For interview requests, image assets, or fact-checks, please contact our communications team directly.